Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriatic Arthritis AND Psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    192 result(s) found for: Psoriatic Arthritis AND Psoriasis. Displaying page 3 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-004439-22 Sponsor Protocol Number: CAIN457F2312 Start Date*: 2013-04-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term effi...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002793-39 Sponsor Protocol Number: 0451 Start Date*: 2018-03-13
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005518-16 Sponsor Protocol Number: U3P Start Date*: 2021-05-10
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10037162 Psoriatic arthropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004757-28 Sponsor Protocol Number: RR07/8350 Start Date*: 2009-03-02
    Sponsor Name:University of Leeds
    Full Title: A randomised controlled single-blind trial to compare intensive management vs standard care in early psoriatic arthritis
    Medical condition: Newly diagnosed psoriatic arthritis of less than two years symptom duration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005777-20 Sponsor Protocol Number: TMP-1115_01 Start Date*: 2016-12-12
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
    Full Title: Impact of concomitant Methotrexate on efficacy, safety and adherence of Ustekinumab-treatment in patients with active Psoriatic Arthritis (MUST-Study)
    Medical condition: active psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002478-20 Sponsor Protocol Number: PRECISESTUDY Start Date*: 2022-03-31
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY.
    Medical condition: PSORIATIC ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003668-55 Sponsor Protocol Number: A3921091 Start Date*: 2013-11-07
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. Paedi...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Completed) SK (Completed) HU (Completed) DE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002464-40 Sponsor Protocol Number: M15-998 Start Date*: 2018-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to B...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SE (Completed) DK (Trial now transitioned) PT (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) FI (Completed) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004152-30 Sponsor Protocol Number: M15-554 Start Date*: 2017-08-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologi...
    Medical condition: Moderately to Severely Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) GR (Completed) PT (Completed) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003214-41 Sponsor Protocol Number: CNTO1959PSA3003 Start Date*: 2019-01-22
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthrit...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) ES (Completed) PL (Completed) PT (Completed) HU (Completed) BG (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004284-98 Sponsor Protocol Number: CAIN457A02001B Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
    Medical condition: Psoriatic Arthritis, Ankylosing Spondylitis, non-radiographic axial spondyloarthritis, Severe Chronic Plaque Psoriasis, moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076297 Non-radiographic axial spondyloarthritis LLT
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003182-17 Sponsor Protocol Number: 1407-0004 Start Date*: 2020-09-30
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, proof-of-concept trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis
    Medical condition: psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Completed) BG (Completed) GB (GB - no longer in EU/EEA) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004477-32 Sponsor Protocol Number: CAIN457F2366 Start Date*: 2017-03-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered secukinumab monotherapy compared with subcutaneously administered ad...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) GB (Completed) ES (Completed) GR (Completed) SK (Completed) DK (Completed) FI (Completed) NL (Completed) CZ (Completed) PT (Completed) HU (Completed) IS (Completed) BG (Completed) LT (Completed) LV (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003113-94 Sponsor Protocol Number: M16-244 Start Date*: 2016-12-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety with Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) FI (Completed) ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011720-59 Sponsor Protocol Number: PsA001 Start Date*: 2010-04-22
    Sponsor Name:SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
    Full Title: PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ADULT ONSET ACTIVE AND PROGRESSIV...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) GB (Completed) BE (Completed) HU (Completed) NL (Completed) CZ (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001695-26 Sponsor Protocol Number: FARM1275JK Start Date*: 2018-09-12
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Monitoring the effectiveness and safety of biological drugs for treatment of psoriasis through evaluation of clinical and biological markers
    Medical condition: Moderate to severe psoriasis and joint disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012264-14 Sponsor Protocol Number: CNTO1275PSA3001 Start Date*: 2009-12-29
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Phase 3 Multicenter, Randomized, Double-blind, Placebo controlled trial of Ustekinumab, a Fully Human anti-IL 12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ps...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) DE (Completed) GB (Completed) LT (Completed) AT (Completed) FI (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004585-25 Sponsor Protocol Number: I1F-MC-RHCF Start Date*: 2017-05-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018188 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) SE (Completed) DK (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005097-10 Sponsor Protocol Number: IM011-054 Start Date*: 2021-08-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Diseas...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003697-17 Sponsor Protocol Number: CNTO1959PSA2001 Start Date*: 2015-04-22
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:41:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA